Is blinatumomab considered chemotherapy?
Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients with B Acute Lymphoblastic Leukemia
A type of blood and bone marrow cancer which mainly affects the white blood cells.
Are there any adverse events with blinatumomab? A total of 24% of the patients in each treatment group underwent allogeneic stem-cell transplantation. Adverse events of grade 3 or higher were reported in 87% of the patients in the blinatumomab group and in 92% of the patients in the chemotherapy group.
Which is better for remission, blinatumomab or chemotherapy? Rates of complete remission with full hematologic recovery and complete remission with full, partial, or incomplete hematologic recovery were significantly higher with blinatumomab therapy than with chemotherapy, and the median duration of remission was longer.
How does NEJM-blinatumomab work for cancer patients? Blinatumomab binds simultaneously to CD3-positive cytotoxic T cells and to CD19-positive B cells, which allows the patient’s endogenous T cells to recognize and eliminate CD19-positive ALL blasts. 14-16
How long does blinatumomab stay in your system? Among the patients who had complete remission with full, partial, or incomplete hematologic recovery, the median duration of remission was 7.3 months (95% CI, 5.8 to 9.9) in the blinatumomab group and 4.6 months (95% CI, 1.8 to 19.0) in the chemotherapy group.
What are the side effects of blinatumomab treatment?
What are the side effects of blinatumomab treatment? Blood monitoring is recommended during treatment because of the haematological effects. Severe neurological events also occurred with blinatumomab and included encephalopathy, convulsions, speech disorders, confusion and problems with coordination and balance.
Why does blinatumomab cause cytokine release syndrome? Some patients develop cytokine release syndrome and it has been suggested that the reaction in severe form may be due to abnormal macrophage activation triggered by cytokines released by blinatumomab-activated cytotoxic T cells leading to haemophagocytic lymphohistiocytosis (HLH).
How is blinatumomab used in NHLs clinical trials? Blinatumomab was first explored in advanced refractory B-cell non-Hodgkin’s lymphomas (NHLs) . Consistent with the short half-life of MT103, the clinical program investigated escalating doses of 0.5–90 µg/m  per day administered by continuous infusion via a portable pump over 4–8 weeks .
How often do you get dexamethasone with blinatumomab? Maintenance treatment with blinatumomab was given as a 4-week continuous infusion every 12 weeks. Patients in the blinatumomab group who had high tumor load during screening were to receive dexamethasone before the start of treatment to prevent the cytokine release syndrome (Table S1 in the Supplementary Appendix ).